key: cord-0995394-yagu9ab8
authors: Hassaniazad, Mehdi; Eftekhar, Ebrahim; Inchehsablagh, Behnaz Rahnama; Kamali, Hossein; Tousi, Abdolali; Jaafari, Mahmoud Reza; Rafat, Milad; Fathalipour, Mohammad; Nikoofal‐Sahlabadi, Sara; Gouklani, Hamed; Alizade, Hesam; Nikpoor, Amin Reza
title: A triple‐blind, placebo‐controlled, randomized clinical trial to evaluate the effect of curcumin‐containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID‐19 patients
date: 2021-09-19
journal: Phytother Res
DOI: 10.1002/ptr.7294
sha: c6c4a0738696948b684fc4eb24f7e4276eeaafbc
doc_id: 995394
cord_uid: yagu9ab8

In COVID‐19 patients, cytokine storm due to excessive immune responses can cause severe complications. In this study, we investigated the effect of curcumin nanomicelles on clinical outcome and cellular immune responses subtypes changes in COVID‐19 patients. A randomized, triple‐blinded, placebo‐controlled study was done. Forty COVID‐19 patients were included into two groups of nano‐curcumin and placebo. The nano‐curcumin group received 40 mg of nano‐curcumin capsule, four times per day for 2 weeks. Clinical signs and gene expression of TBX21, GATA3, RORC and FOXP3 genes and IFN‐γ, IL‐4, IL‐17 and TGF‐β cytokines serum levels were measured at time points of 0, 7 and 14 days. Serum levels of IFN‐γ (p = .52) and IL‐17 (p = .11) decreased, while IL‐4 (p = .12) and TGF‐β (p = .14) increased in the nano‐curcumin group compared with placebo on day 14. Moreover, gene expressions of TBX21 (p = .02) and FOXP3 (p = .005) genes were significantly decreased and increased between nano‐curcumin and placebo groups on day 7, respectively. It can be concluded that administration of nano‐curcumin in inflammatory phase of COVID‐19 can accelerate recovering of the acute inflammatory phase by modulating inflammatory immune responses. Therefore, it is suggested that this supplement in inflammatory diseases, including COVID‐19, can be effective in controlling the inflammatory responses.

In COVID-19 patients, cytokine storm due to excessive immune responses can cause severe complications. In this study, we investigated the effect of curcumin nanomicelles on clinical outcome and cellular immune responses subtypes changes in COVID-19 patients. A randomized, triple-blinded, placebo-controlled study was done.

Forty COVID-19 patients were included into two groups of nano-curcumin and placebo. The nano-curcumin group received 40 mg of nano-curcumin capsule, four times per day for 2 weeks. Clinical signs and gene expression of TBX21, GATA3, RORC and FOXP3 genes and IFN-γ, IL-4, IL-17 and TGF-β cytokines serum levels were measured at time points of 0, 7 and 14 days. Serum levels of IFN-γ (p = .52) and IL-17 (p = .11) decreased, while IL-4 (p = .12) and TGF-β (p = .14) increased in the nanocurcumin group compared with placebo on day 14. Moreover, gene expressions of TBX21 (p = .02) and FOXP3 (p = .005) genes were significantly decreased and increased between nano-curcumin and placebo groups on day 7, respectively. It can be concluded that administration of nano-curcumin in inflammatory phase of COVID-19 can accelerate recovering of the acute inflammatory phase by modulating inflammatory immune responses. Therefore, it is suggested that this supplement in inflammatory diseases, including COVID-19, can be effective in controlling the inflammatory responses. , is associated with broad signs from mild flu symptoms to high risk of acute respiratory distress syndrome and mortality (Huang et al., 2020) . Patients with COVID-19 may face excessive immune responses followed by serious and life-threatening pulmonary damage. In response to the virus, the immune cells may produce a large amount of inflammatory cytokines, which cause dangerous phenomenon of cytokine storms. In fact, cytokine release syndrome is one of the leading causes of severe lungs damage and death in COVID-19 patients (Conti et al., 2020; Ghaebi, Osali, Valizadeh, Roshangar, & Ahmadi, 2020) .

Curcumin, a traditional herb, is one of the derivatives of Curcuma longa (turmeric). Several in-vivo and in-vitro studies have shown that curcumin and its analogs significantly inhibit the production and secretion of pro-inflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF-α (Garg, Ahuja, Sankar, Kumar, & Moss, 2012; He et al., 2015) . In this regard, animal studies have investigated the role of curcumin in inflammatory lung involvement, and their results showed that curcumin could actively reduce IL-1b, IL-6 and TNF-α cytokines following the infectious lung injuries. In addition, curcumin can reduce productions of several cytokines and chemokines, such as MCP1, MIPI1, CXCL family, SDF1 and MMP family (Dai et al., 2018; Sordillo & Helson, 2015) . The mechanism of immunomodulation of curcumin is widely investigated (Biswas, McClure, Jimenez, Megson, & Rahman, 2005) . First, curcumin prevents activation of IKKb (Cohen, Veena, Srivatsan, & Wang, 2009 ). Second, curcumin increases expression of IkBa (Jobin et al., 1999) . Third, curcumin activates AMPK (Han, Xu, Guo, & Huang, 2018) and inhibits nuclear translocation of NF-kB and P65, which ultimately reduces inflammation .

Another inflammatory mediator regulated by curcumin is cycloxygenase 2 (COX-2) (Khan & Khan, 2018) . Therefore, curcumin is probably able to shift immune responses through the abovementioned mechanisms. The balance of immune responses in infectious and non-infectious diseases plays an important role in the prognosis of the diseases. The main cellular immune responses are including T helper1, T helper2, T Regulatory and T helper 17 lymphocytes responses, which shifting balances towards each of these responses can change the immune system condition (McMichael & Rowland-Jones, 2001) . Curcumin can also prevent the accumulation and migration of a wide range of immune cells, including peripheral mononuclear cells (PMNs) cells, CD4+ and CD8+ T lymphocytes and NK cells (Avasarala et al., 2013) .

Curcumin also has antiviral effects on, such as, respiratory syndrome virus (RSV) (Yang, Li, Li, Wang, & Huang, 2017) On the other hand, despite curcumin's enormous beneficial properties, it has major limitations in administration due to its physicochemical properties. Among these limitations are the low aqueous solubility, low bioavailability and its low absorption from the gastrointestinal tract, which prevents its proper functions. Therefore, nanoformulations of curcumin such as nanomicelles have been synthetized, which improve absorption, increase bioavailability and thus provide a suitable replacement for conventional form of curcumin (Gera et al., 2017; Hatamipour, Sahebkar, Alavizadeh, Dorri, & Jaafari, 2019) .

Paying attention to the cytokine storm caused by SARAS-COV-2 virus, as well as the antiinflammatory efficacy of curcumin-containing nanomicelles, in the present study, we studied the effect of curcumincontaining nanomicelles on the T lymphocyte cells immune responses balance including T helper1, T helper 2, T regulatory and T helper 17 cells and its clinical outcome in the treatment of COVID-19.

The study protocol of the present was published previously (Hassaniazad et al., 2020) . This is a randomized, triple-blinded, placebo-controlled study. A total of 40 COVID-19 patients were included, who were referred to COVID-19 wards of Shahid Mohammadi Hospital, Bandar Abbas, Iran. To have the most baseline homogeneity, the patients were divided randomly into the groups of nano-curcumin and placebo using Excel software randomization method. For this purpose, a participant's variable equal to the number of participants in the two groups of placebo and nano-curcumin was defined in Excel software. Then, using the randomization function, the participants list containing two groups of placebo and nano-curcumin were randomly assigned, and the patients admitted to the study were allocated to the groups according to the randomly created list.

Patients in both groups received treatment in accordance with the latest version of the COVID-19 treatment guideline, and inclusion into the study did not interfere with the main treatments (Table 1 ). An Real-Time PCR test. The exclusion criteria also were as follows: pregnancy or lactation, allergy to turmeric or curcumin, smoking, patient connected to the ventilator, SaO 2 less than 90% or PaO 2 less than 8 kPa, having comorbidities (such as severe renal failure, glomerular filtration rate less than 30 ml/min, liver failure, congestive heart failure or chronic obstructive pulmonary disease), history of gallstones, history of gastritis or active gastrointestinal ulcer. The obtained demographic data, clinical and laboratory parameters are summarized in Tables 2 and 3.

The sample size was calculated according to the Sakpal et al.'s study (Sakpal, 2010) and based on the comparing two proportions formula.

To have a two arm designed clinical trial with 80% power and twosided 5% significance, and given the efficacy of nano-curcumin in previous COVID-19 clinical trial study (Saber-Moghaddam et al., 2021) , 20 sample size in each arm of the study was calculated.

The tested medication in this trial was an herbal supplement containing soft gels containing curcuminoids nanomicelles. This drug has been commercialized and registered as the Sinacurcumin ® soft gel 40 mg by Exir Nano Sina Company, Tehran, Iran (IRC:1228225765).

The nano-curcumin group participants received Sinacurcumin ® soft gel 40 mg, four times per day (after breakfast, lunch, dinner and before bedtime) for 2 weeks. In the placebo group, capsules with the same appearance and characteristics (placebo capsules, Exir Nano Sina Company, Tehran, Iran) were prescribed, similar to the nano-curcumin administration. In order to blind, the coded capsule containers method for nano-curcumin and placebo capsules were used to have the tripleblinded RCT for the participants, physicians and nurses collaborating in the study and data collectors. The capsule containers were coded in such a way that none of the participants, physicians and nurses collaborating in the study and data collectors knew about the coding. The capsules were then given in order of their codes to the patients entered the study. Assessing participant compliance was also done by methods of patient self-reporting of medication use as well as counting of unused capsules in every visit by the physician and calculating the patient's compliance (Lafleur & Oderda, 2004) . In case of deterioration of the patient and inconsistency with the inclusion criteria of the study, the patient was excluded from the study and received the necessary treatment according to the guidelines. Also, there were no co-interventions for the participants in the present trial ( Figure 1 ).

Blood samples of all participants were collected three times of days 0, 7 and 14 after administration of the nano-curcumin or placebo. Bloods were centrifuged at 3000 rpm, and serum was separated in different microtubes and stored at À80 C until cytokine assay.

Complete clinical symptoms and laboratory findings including peripheral blood and serum parameters including lactate dehydrogenase (LDH), white blood cells (WBC) count, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR) and C-T A B L E 1 Medications and supplements intake in two groups of placebo and nano-curcumin Table 4 . The GAPDH, as the housekeeping gene, was also used to normalize the transcript level of the target genes.

Real-time PCR was performed triplicates for every sample. Finally, mRNA expression levels were obtained using the 2 ÀΔΔCT method,

where ΔCt = target gene Ct À housekeeping gene Ct.

To evaluate the COVID-19 patients' serum level of IFN-γ, IL-4, IL-17

and TGF-β cytokines at days 0, 7 and 14 following treatments by proportions between the groups. The p value lower than .05 was considered as significant.

According to the inclusion criteria, 40 patients were eligible to enroll in the study, 20 patients in nano-curcumin and 20 patients in placebo group completed the 2 weeks duration trial. As seen in Table 1 , there were no significant differences between prescribed medications and supplements between placebo and nano-curcumin groups. Also, the baseline-characteristics of patients at the time of enrollment are summarized in Table 2 . The demographics and clinical characteristics were not statistically different between nano-curcumin and placebo groups at the time of enrollment.

All the subjects were evaluated in terms of clinical signs and symptoms including fever, oxygen saturation level, myalgia, cough, sore throat, headache, anosmia and laboratory indices such as cell blood As shown in Table 3 , there were no statistically significant differences in the clinical manifestations between nano-curcumin and placebo groups after the treatment at 0, 7 and 14 days. As seen in Table 3 , despite the lack of significant differences, the CRP level in patients decreased in the second week after nano-curcumin administration compared with placebo group, so that 5% of patients in nanocurcumin group had the CRP level more than +2, compared with 20% of patients in placebo group.

The laboratory findings are also shown in Figure 2 . One of the remarkable findings, despite the lack of statistically significant difference between the placebo and nano-curcumin groups, was the increase in the mean percentage of lymphocytes in the nano-curcumin group compared with the placebo. The mean percentage of lymphocytes in nano-curcumin group on days 7 and 14 was 31.6% ± 13.3 and 32.6% ± 12.8, respectively, while this frequency was observed in the placebo group as 23.5% ± 13.3 and 29.7 ± 11.8 on days 7 and 14, respectively. This trend was also observed for other laboratory indices such as neutrophils percent, neutrophil to lymphocyte ratio (NLR) and LDH activity (Figure 2 ). It should be mentioned that no specific adverse reactions related to curcumin were observed in nanocurcumin receiving patients. 

COVID-19 outbreak, which has been a pandemic since 2020, has caused many deaths worldwide by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many efforts have been made to achieve an effective therapeutic strategy for it, but no definitive approach has been reached to date. It has been shown that the excessive immune centered on CD8 T lymphocytes, macrophages, due to IFN-γ and IL-12 cytokine secretions (Bruder, Srikiatkhachorn, & Enelow, 2006; Farhood et al., 2019; Farrar & Schreiber, 1993 According to our results, inflammatory cytokines including IL-17

and IFN-γ were decreased, but TGF-β and IL-4 cytokines were ele- However, the limitations of the present study were the small sample size as well as the short treatment time. The short duration of treatment time was due to short duration of the disease and limitations of patients' follow-up after discharging from the hospital.

In conclusion, the results of the present clinical trial study suggest that the use of nanomicelles containing curcumin in COVID-19 patients can improve peripheral blood inflammatory indices 7 days after intervention. Also, using nano-curcumin can modulate the immune responses by decreasing Th1 and Th17 responses and increasing T regulatory responses and further reducing the IL-17 and IFN-γ and increasing the suppressive cytokines TGF-β and IL-4. Therefore, it can be concluded that nano-curcumin can accelerate the process of recovery from the acute inflammatory phase of COVID-19 disease.

The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebocontrolled trial

Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome

A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health

The role of neutrophil to lymphocyte count ratio in the differential diagnosis of pulmonary tuberculosis and bacterial communityacquired pneumonia: A cross-sectional study at Ayder and Mekelle Hospitals

Curcumin induces glutathione biosynthesis and inhibits NF-κB activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity

Cellular immunity and lung injury in respiratory virus infection

Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Iκβ kinase

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies

Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways

Dietary curcumin: Correlation between bioavailability and health potential

The effects of nano-curcumin supplementation on Th1/Th17 balance in migraine patients: A randomized controlled clinical trial

The molecular cell biology of interferon-gamma and its receptor

Curcumin for maintenance of remission in ulcerative colitis

Nanoformulations of curcumin: An emerging paradigm for improved remedial application

Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances

Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production

The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial

Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids

Curcumin, inflammation, and chronic diseases: How are they linked?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Curcumin blocks cytokinemediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity

Curcumin: A modulator of inflammatory signaling pathways in the immune system

Antiviral potential of natural compounds against influenza virus hemagglutinin

Nano-gold displayed anti-inflammatory property via NF-kB pathways by suppressing COX-2 activity

Methods to measure patient compliance with medication regimens

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

Cellular immune responses to HIV

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?

Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial

Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial

Sample size estimation in clinical trial

Anti-inflammatory action of curcumin and its use in the treatment of lifestyle-related diseases

Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-κB signaling pathway

Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection

A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients

The authors thank the staff of COVID-19 ward and the Laboratory Department of Shahid Mohammadi Hospital, Bandar Abbas, Iran, for their cooperation in this study.

Prof. Mahmoud Reza Jaafari, one of the co-authors, founded Exir Nano Sina Company, a Nano pharmaceutical company. The other coauthors declare no conflict of interest.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

https://orcid.org/0000-0001-5619-8771